Atea Pharmaceuticals (AVIR) EBITDA (2019 - 2026)

Atea Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at -$45.7 million for Q1 2026.

• In Q1 2026, EBITDA fell 32.93% year-over-year to -$45.7 million; the TTM figure through Mar 2026 stood at -$169.7 million (down 21.94% YoY), while the FY2025 annual figure was -$158.4 million, up 5.91% from the prior year.
• EBITDA was -$45.7 million for Q1 2026 at Atea Pharmaceuticals, down from -$44.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$8.9 million in Q3 2022 to a low of -$63.6 million in Q1 2024.
• Historically, EBITDA has averaged -$36.7 million across 5 years, with a median of -$35.1 million in 2023.
• Biggest YoY gain for EBITDA was 68.36% in 2022; the steepest drop was 460.71% in 2022.
• A 5-year view of EBITDA shows it stood at -$34.3 million in 2022, then retreated by 12.95% to -$38.7 million in 2023, then increased by 12.26% to -$34.0 million in 2024, then slumped by 32.34% to -$44.9 million in 2025, then decreased by 1.74% to -$45.7 million in 2026.
• The last three EBITDA figures came in at -$45.7 million (Q1 2026), -$44.9 million (Q4 2025), and -$41.8 million (Q3 2025), per Business Quant data.